Pandemic & Infectious Disease — 2026-07-17

Active Outbreak Tracker

3 sources

cdc.gov

Ebola Outbreak: Current Situation | Ebola | CDC

cdc.gov

Information for Travelers Returning from Ebola-Affected Areas | Ebola | CDC

cdc.gov

Domestically Acquired Cyclosporiasis Cases in Multiple U.S. States, 2026 | HAN | CDC

Cyclosporiasis — United States

• Status: 1,645 domestically acquired cases confirmed across 34 states since May 1, 2026; Growing cluster of 400+ cases in Michigan, Ohio, West Virginia, and Kentucky.
• Key Development: Official case counts likely capture only a fraction of actual U.S. cyclosporiasis infections, with the outbreak expected to accelerate further. Investigators have identified a multistate cluster potentially linked to a common food source. Healthcare providers are being alerted to recognize and report suspected cases.
• Response: CDC has issued formal health alerts to healthcare workers. The agency is investigating the multistate cluster and tracking potential food contamination sources.

Ebola — Democratic Republic of Congo and Uganda

• Status: Ongoing transmission in Central Africa with expanding outbreak. WHO declared this a Public Health Emergency of International Concern in May 2026.
• Key Development: Ebola outbreak continues to outpace response capacity in the region. The outbreak is growing despite containment efforts, with responders struggling to keep pace with new infections and case identification.
• Response: International organizations including MSF and WHO are coordinating response efforts. However, resources remain constrained, and the outbreak's trajectory suggests continued escalation is likely.

Respiratory Illnesses — United States

• Status: Acute respiratory illness activity remains very low nationwide as of July 10, 2026.
• Key Development: CDC will begin flu and RSV updates for the next respiratory illness season in Fall 2026. Current activity levels do not warrant heightened alerts.
• Response: Routine surveillance continues; no emergency response measures currently needed.

Vaccine & Treatment Pipeline

• 2025–2026 COVID-19 Vaccines (multiple manufacturers): Updated vaccines showed effectiveness against medically attended disease and hospitalizations among immunocompetent adults. Protection demonstrated against ED/UC visits and severe outcomes.

• mRNA Influenza Vaccine (mFlusiva, Moderna): FDA panel supported advancement. Expected regulatory decisions anticipated in Q3 2026 (August/September timeline).

• FDA Drug Approvals Expected August 2026: Treatments for HIV, influenza, and other infectious diseases are under regulatory review with decisions pending.

Expert Analysis

The WHO confirmed on July 17 that the global hantavirus outbreak—which became a major threat earlier in 2026—has now officially concluded. This represents a significant public health victory, though the declaration comes as other outbreaks demand urgent attention. However, pandemic preparedness experts warn that recent leadership transitions and shifts in global health priorities pose new risks. According to analysis published in The Lancet Infectious Diseases in late November 2024, concerns have grown about "the future of global health and pandemic preparedness" following political transitions that may reduce international coordination and funding for disease surveillance systems.

The cyclosporiasis outbreak presents an immediate challenge that underscores ongoing vulnerabilities in U.S. food safety and outbreak detection. As noted in WIRED reporting, official case counts are likely capturing only a fraction of actual infections, with the true burden significantly higher. The multistate cluster concentrated in the Midwest suggests a common source—potentially imported fresh produce—that investigators are actively pursuing. Epidemiologists emphasize that without rapid identification of the contaminated food source, case counts will continue to climb through late summer.

Looking ahead, public health officials stress that spillover prevention and pandemic preparedness must remain priorities. The WHO and supporting institutions are advocating for sustained investment in early warning systems and international coordination mechanisms, even as political attention to infectious disease wanes globally.

Global Health Security

WHO Pandemic Preparedness Framework: The UN is convening a High-Level Meeting on pandemic prevention, preparedness, and response in 2026 to refocus global attention on spillover prevention and outbreak response capacity following the COVID-19 pandemic. Experts are calling for bolstered research pipelines specifically targeting emerging viral threats—including filoviruses (Ebola, Marburg) and other zoonotic pathogens.

CDC and State Health Department Coordination: Cyclosporiasis response demonstrates ongoing integration between federal and state agencies, though resource constraints remain evident. The CDC's HAN (Health Alert Network) system continues to serve as the backbone for rapid provider notification during multistate outbreaks.

What to Watch Next

• Late summer cyclosporiasis surge: Case counts are expected to accelerate further as warm weather continues and contaminated produce may remain in supply chains. Identify of the primary food source is critical to containment.

• Q3 2026 FDA approvals (August–September): Multiple infectious disease treatments and the mRNA influenza vaccine are anticipated to receive regulatory decisions, potentially expanding therapeutic options before fall respiratory illness season.

• Ebola outbreak trajectory in Central Africa: Continued expansion or containment will depend on resource allocation, local cooperation with response teams, and containment measures in Uganda and DRC. The outbreak remains a significant international public health threat.